BOSTON ( TheStreet) -- News of a drug's approval or rejection from the U.S. Food and Drug Administration can rock or kill a biotech stock's price. Here are ten companies with drugs facing FDA approval decisions in the first half of this year.
Xenoport ( XNPT) Drug/indication: Horizant for restless leg syndrome Approval decision date: Unknown Xenoport said that the FDA extended the Horizant approval decision date to Feb. 11 from Feb. 9 due to severe winter weather that shut down Washington. Yet the Feb. 11 deadline came and went without any word on the drug's approval. GlaxoSmithKline ( GSK) is Xenoport's marketing partner for Horizant. Update: The FDA rejected Horizant Wednesday night, citing concerns about a potential link between the drug and pancreatic tumors in rats.